Literature DB >> 10840462

IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis.

R B Nadler1, A E Koch, E A Calhoun, P L Campbell, D L Pruden, C L Bennett, P R Yarnold, A J Schaeffer.   

Abstract

PURPOSE: Chronic Prostatitis, or Chronic Pelvic Pain Syndrome [CPPS], is a common disorder characterized by pelvic pain and varying degrees of inflammation in expressed prostatic secretions (EPS). In search of markers to more clearly define CPPS, we compared proinflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) levels in EPS from men with CPPS, to healthy men and men with Benign Prostatic Hyperplasia (BPH).
METHODS: 78 men: controls (n = 16), BPH (n = 14), CPPS IIIA [>/=10 white blood cells per high power field (WBC/hpf) in EPS] (n = 18), CPPS IIIB [<10 WBC/hpf in EPS] (n = 20), and asymptomatic inflammatory prostatitis (AIP) (n = 10) were evaluated for EPS WBC, and IL-1beta and TNF-alpha by ELISA.
RESULTS: IL-1beta and TNF-alpha levels in EPS were usually detectable in men with CPPS IIIA (89% and 45%, respectively) or AIP (90%; 100%), but less often in controls (31%; 17%), BPH (57%; 15%), and CPPS IIIB (35%; 15%) respectively. IL-1beta and TNF-alpha levels were higher in CPPS IIIA versus CPPS IIIB, and in AIP versus controls or BPH (p's <0.001). Cut-points for IL-1beta and TNF-alpha discriminated AIP from controls (predictive values = 94% and 83%, respectively) and CPPS IIIA from CPPS IIIB (predictive values 84% and 100%). Overall, there was a correlation between IL-1beta and TNF-alpha (p <0.003), but no correlation between WBC and IL-1beta (p <0.1) or TNF-alpha (p <0.50).
CONCLUSIONS: Cytokines are frequently present and elevated in the EPS from men with CPPS IIIA and AIP and provide a novel means for identification, characterization and potential management of men with CPPS that differs from traditional methods based on WBC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840462

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  55 in total

1.  Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators.

Authors:  Praveen Thumbikat; Shiva Shahrara; Rudina Sobkoviak; Joseph Done; Richard M Pope; Anthony J Schaeffer
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

2.  Special Report on Prostatitis: State of the Art: Highlights of the Third Annual International Prostatitis Collaborative Network Meeting October 23-25, 2000, Washington, DC.

Authors:  J C Nickel
Journal:  Rev Urol       Date:  2001

3.  Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2.

Authors:  Yijie Cheng; Yanfang Cao; Awais Ullah Ihsan; Farhan Ullah Khan; Xue Li; Dianyou Xie; Xingxing Cui; Wenlu Wang; Ziwei Liu; Cunyu Li; Khalil Ali Ahmad; Kiganda Raymond Sembatya; Reyaj Mikrani; Xiaohui Zhou
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

4.  CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis.

Authors:  Marsha L Quick; Soumi Mukherjee; Charles N Rudick; Joseph D Done; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-18       Impact factor: 3.619

5.  The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3.

Authors:  Koh Takeyama; Hiroaki Mitsuzawa; Chiaki Nishitani; Takeyuki Shimizu; Hitomi Sano; Yasuharu Kunishima; Satoshi Takahashi; Hiroshi Hotta; Masanori Matsukawa; Ken-Ichiro Shibata; Taiji Tsukamoto; Yoshio Kuroki
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

6.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

Review 7.  Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment.

Authors:  Michel A Pontari
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Mechanisms in prostatitis/chronic pelvic pain syndrome.

Authors:  Michel A Pontari; Michael R Ruggieri
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

9.  Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome.

Authors:  Naresh V Desireddi; Phillip L Campbell; Jeffrey A Stern; Rudina Sobkoviak; Shannon Chuai; Shiva Shahrara; Praveen Thumbikat; Richard M Pope; J Richard Landis; Alisa E Koch; Anthony J Schaeffer
Journal:  J Urol       Date:  2008-03-18       Impact factor: 7.450

Review 10.  Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link.

Authors:  Rajiv Saini; Ricardo R Gonzalez; Alexis E Te
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.